O
Olivia Pagani
Researcher at Geneva College
Publications - 164
Citations - 11126
Olivia Pagani is an academic researcher from Geneva College. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 44, co-authored 145 publications receiving 9092 citations. Previous affiliations of Olivia Pagani include University of Geneva.
Papers
More filters
Journal ArticleDOI
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fatima Cardoso,Ana Costa,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,G. Bhattacharyya,Laura Biganzoli,Maria João Cardoso,Lisa A. Carey,D. Corneliussen-James,Giuseppe Curigliano,Véronique Diéras,N.S. El Saghir,Alex Eniu,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Alessandra Gennari,Nadia Harbeck,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Musa Mayer,H. Meijer,Shirley Mertz,S. Ohno,Olivia Pagani,E. Papadopoulos,Fedro A. Peccatori,Frédérique Penault-Llorca,Martine Piccart,Jean-Yves Pierga,Hope S. Rugo,Lillie D. Shockney,George W. Sledge,Sandra M Swain,Christoph Thomssen,Andrew Tutt,Daniel A. Vorobiof,Binghe Xu,Larry Norton,Eric P. Winer +44 more
TL;DR: This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients, and provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care.
Journal ArticleDOI
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano,Harold J. Burstein,Eric P. Winer,Michael Gnant,Peter Dubsky,Sibylle Loibl,Marco Colleoni,Meredith M. Regan,Martine Piccart-Gebhart,H.-J. Senn,Beat Thürlimann,Fabrice Andre,José Baselga,Jonas Bergh,Hervé Bonnefoi,Sara Y. Brucker,Fatima Cardoso,Lisa A. Carey,Eva Ciruelos,Jack Cuzick,Carsten Denkert,A. Di Leo,Bent Ejlertsen,Prudence A. Francis,Viviana Galimberti,Judy Garber,Bahadir M. Gulluoglu,Pamela J. Goodwin,Nadia Harbeck,Daniel F. Hayes,Chiun-Sheng Huang,Jens Huober,H. Khaled,Jacek Jassem,Zefei Jiang,Per Karlsson,Monica Morrow,Roberto Orecchia,Kent Osborne,Olivia Pagani,Ann H. Partridge,Kathleen I. Pritchard,Jungsil Ro,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Zhimin Shao,I.E. Smith,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Toshihiro Watanabe,Timothy J. Whelan,Bo Xu +53 more
TL;DR: The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer, and recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence.
Journal ArticleDOI
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani,Meredith M. Regan,Barbara Walley,Gini F. Fleming,Marco Colleoni,István Láng,Henry L. Gomez,Carlo Tondini,Harold J. Burstein,Edith A. Perez,Eva Ciruelos,Vered Stearns,Hervé Bonnefoi,Silvana Martino,Charles E. Geyer,Graziella Pinotti,Fabio Puglisi,Diana Crivellari,Thomas Ruhstaller,Eric P. Winer,Manuela Rabaglio-Poretti,Rudolf Maibach,Barbara Ruepp,Anita Giobbie-Hurder,Karen N. Price,Jürg Bernhard,Weixiu Luo,Karin Ribi,Giuseppe Viale,Alan S. Coates,Richard D. Gelber,Aron Goldhirsch,Prudence A. Francis +32 more
TL;DR: In premenopausal women with hormone-receptor-positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppressed, significantly reduced recurrence.
Journal ArticleDOI
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fatima Cardoso,Ana Costa,Larry Norton,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,Laura Biganzoli,Kimberly L. Blackwell,Maria João Cardoso,Tanja Cufer,N.S. El Saghir,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Sharon H. Giordano,Joseph Gligorov,A. Goldhirsch,Nadia Harbeck,Nehmat Houssami,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Stella Kyriakides,U. N. Lin,Musa Mayer,S. D. Merjaver,E. B. Nordström,Olivia Pagani,A.H. Partridge,Frédérique Penault-Llorca,Martine Piccart,Hope S. Rugo,George W. Sledge,Christoph Thomssen,L.J. van 't Veer,Daniel A. Vorobiof,Conny Vrieling,N. West,Bo Xu,Eric P. Winer +42 more
TL;DR: Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease, although the range is wide, and survival may be longer for patients treated in specialized institutions and within each country.
Journal ArticleDOI
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A. Francis,Prudence A. Francis,Olivia Pagani,Gini F. Fleming,Barbara Walley,M.A. Colleoni,István Láng,Henry L. Gomez,Carlo Tondini,Eva Ciruelos,Harold J. Burstein,H. Bonnefoi,Meritxell Bellet,Silvana Martino,Charles E. Geyer,Matthew P. Goetz,Vered Stearns,Graziella Pinotti,Fabio Puglisi,S. Spazzapan,Miguel Angel Climent,Lorenzo Pavesi,Thomas Ruhstaller,Nancy E. Davidson,Robert E. Coleman,Marc Debled,Stefan Buchholz,JN Ingle,Eric P. Winer,Rudolf Maibach,Manuela Rabaglio-Poretti,Barbara Ruepp,A. Di Leo,Alan S. Coates,Richard D. Gelber,A. Goldhirsch,Meredith M. Regan +36 more
TL;DR: Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8‐year rates of both disease‐free and overall survival than tamox ifen alone and the use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence.